

CITATION REPORT

List of articles citing

Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial

DOI: 10.1111/dme.12999

Diabetic Medicine, 2016, 33, 1299-301.

Source: <https://exaly.com/paper-pdf/63446479/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
7	The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism. <i>Endocrine</i> , 2018 , 59, 602-613	4	10
6	PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes. <i>International Journal of Endocrinology</i> , 2019 , 2019, 3054820	2.7	4
5	Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue. <i>International Journal of Endocrinology</i> , 2020 , 2020, 7078108 ^{2.7}	2.7	4
4	Priming metabolism with the type 5 phosphodiesterase: the role of cGMP-hydrolyzing enzymes. <i>Current Opinion in Pharmacology</i> , 2021 , 60, 298-305	5.1	1
3	A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure. <i>Clinical Science</i> , 2020 , 134, 473-512	6.5	12
2	Update of Indoles: Promising molecules for ameliorating metabolic diseases.. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 150, 112957	7.5	0
1	The efficacy of PDE5 inhibitors in diabetic patients.		2